As demonstrated in vitro in cultured adipocytes (166, 167) and in vivo in Zucker rats (167), GIP enhances the activity of lipoprotein lipase (LPL), which promotes adipose tissue lipid disposal by enhancing hydrolytic cleavage of circulating triglycerides (TAG) into fatty acids (FA) and monoacylglycerol, which gets re-esterified and stored in adipose tissue
[1] [7] Phase 3 trials are reported to be ongoing
How Retatrutide Compares to Other Weight Loss Medications The Triple Agonist Advantage Retatrutide's unprecedented efficacy stems from its unique mechanism as a triple hormone receptor agonist , activating three complementary pathways: GLP-1 (Glucagon-Like Peptide-1): Reduces appetite, slows gastric emptying, improves insulin secretion GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances GLP-1 effects, improves insulin sensitivity, may affect fat metabolism Glucagon: Increases energy expenditure, promotes fat burning, may improve metabolic rate Head-to-Head Comparison Retatrutide's 6.2 percentage point improvement over tirzepatide and 13.7 percentage point improvement over semaglutide represents a substantial therapeutic advance
What if I dont see results? This is exactly why we start with comprehensive lab testing and create personalized protocols